NASDAQ:ADVM - Adverum Biotechnologies Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$5.20 +0.15 (+2.97 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$5.05
Today's Range$5.00 - $5.35
52-Week Range$2.40 - $8.59
Volume458,000 shs
Average Volume993,937 shs
Market Capitalization$329.14 million
P/E Ratio-3.91
Dividend YieldN/A
Beta3.49
Adverum Biotechnologies logoAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-272-6269

Debt

Debt-to-Equity RatioN/A
Current Ratio20.92
Quick Ratio20.93

Price-To-Earnings

Trailing P/E Ratio-3.91
Forward P/E Ratio-4.16
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.85 million
Price / Sales176.21
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.27

Profitability

EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,957.63%
Return on Equity-30.61%
Return on Assets-28.60%

Miscellaneous

Employees78
Outstanding Shares62,690,000
Market Cap$329.14 million

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) released its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.30) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.01. The biotechnology company had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.40 million. Adverum Biotechnologies had a negative net margin of 3,957.63% and a negative return on equity of 30.61%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

3 brokers have issued 12 month target prices for Adverum Biotechnologies' shares. Their predictions range from $6.00 to $12.00. On average, they anticipate Adverum Biotechnologies' stock price to reach $8.6667 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View Analyst Price Targets for Adverum Biotechnologies.

What is the consensus analysts' recommendation for Adverum Biotechnologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adverum Biotechnologies.

Who are some of Adverum Biotechnologies' key competitors?

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 59)
  • Dr. Mehdi Gasmi, Chief Science & Technology Officer (Age 51)
  • Dr. Amber Salzman, Consultant (Age 56)
  • Ms. Leone D. Patterson, Interim Pres, CEO, Sr. VP & CFO (Age 55)
  • Dr. Jennifer Cheng, VP, Gen. Counsel & Corp. Sec. (Age 45)

Has Adverum Biotechnologies been receiving favorable news coverage?

Headlines about ADVM stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adverum Biotechnologies earned a media and rumor sentiment score of 0.02 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.23 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Adverum Biotechnologies.

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.40%), BlackRock Inc. (5.31%), Dimensional Fund Advisors LP (2.58%), FMR LLC (1.73%), Bank of New York Mellon Corp (0.30%) and Millennium Management LLC (0.25%). View Institutional Ownership Trends for Adverum Biotechnologies.

Which major investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Adverum Biotechnologies.

Which major investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., FMR LLC, Cowen Inc., Rhumbline Advisers and MetLife Investment Advisors LLC. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $5.20.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $329.14 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  403
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.